International Stem Cell Corporation to Present at Biotech Showcase 2014
January 07 2014 - 8:30AM
Marketwired
International Stem Cell Corporation to Present at Biotech Showcase
2014
CARLSBAD, CA--(Marketwired - Jan 7, 2014) - International Stem
Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a
California-based biotechnology company developing novel stem cell
based therapies and biomedical products, today announced that
Executive Vice President Dr. Simon Craw, will present a corporate
overview of ISCO and its subsidiaries at the Biotech Showcase™ 2014
on Monday, January 13th at 9:30 a.m. PST. The conference is being
held in San Francisco at the Parc 55 Wyndham Union Square
Hotel.
Biotech Showcase 2014 conference presentation details: Date:
Monday, January 13, 2014 Time: 9:30 a.m. PST Location: Parc 55
Wyndham Union Square Hotel, San Francisco, CA Room: Room Mission II
- Track C Conference details:
http://www.ebdgroup.com/bts/index.php
Please contact the conference organizers if you have an interest
in attending the conference or if you would like to arrange a
meeting with International Stem Cell Corporation's management team.
To register for the event, please visit the conference website at
www.ebdgroup.com/bts/registration/index.php.
Biotech Showcase™ is an investor and partnering conference
devoted to providing private and public biotechnology and life
sciences companies with an opportunity to present to, and meet
with, investors and pharmaceutical executives in one place during
the course of one of the industry's largest annual healthcare
investor conferences. Investors and biopharmaceutical executives
from around the world gather in San Francisco during this critical
week which is widely viewed as setting the tone for the coming
year. For more information, please visit the conference website at
http://www.ebdgroup.com/bts/index.php
ISCO's lead indication is Parkinson's disease. The Parkinson's
disease program uses human parthenogenetic neural stem cells
(hPNSC) a novel therapeutic cellular product derived from the
company's proprietary histocompatible human pluripotent stem cells.
hPNSC are self-renewing mulitpotent cells that are precursors for
the major cells of the central nervous system. The ability of hPNSC
to (i) differentiate into dopaminergic (DA) neurons and (ii)
express neurotrophic factors such as glial derived neurotrophic
factor (GDNF) and brain derived neurotrophic factor (BDNF) to
protect the nigrostriatal system, offers a new opportunity for the
treatment of Parkinson's disease, especially in cases where current
small molecule approaches fail to adequately control the
symptoms.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the
therapeutic applications of human parthenogenetic stem cells
(hpSCs) and the development and commercialization of cell-based
research and cosmetic products. ISCO's core technology,
parthenogenesis, results in the creation of pluripotent human stem
cells from unfertilized oocytes (eggs) hence avoiding ethical
issues associated with the use or destruction of viable human
embryos. ISCO scientists have created the first parthenogenetic,
homozygous stem cell line that can be a source of therapeutic cells
for hundreds of millions of individuals of differing genders, ages
and racial background with minimal immune rejection after
transplantation. hpSCs offer the potential to create the first true
stem cell bank, UniStemCell™. ISCO also produces and markets
specialized cells and growth media for therapeutic research
worldwide through its subsidiary Lifeline Cell Technology
(www.lifelinecelltech.com), and stem cell-based skin care products
through its subsidiary Lifeline Skin Care
(www.lifelineskincare.com). More information is available at
www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company
updates and industry related news, visit:
www.facebook.com/InternationalStemCellCorporation and
www.twitter.com/intlstemcell
Contacts: International Stem Cell Corporation Dr. Simon Craw
Executive Vice President Phone: 760-940-6383 Email:
ir@intlstemcell.com
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Sep 2024 to Oct 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Oct 2023 to Oct 2024